Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Rating Reaffirmed by HC Wainwright

Day One Biopharmaceuticals (NASDAQ:DAWN)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports. They currently have a $50.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 278.50% from the company’s current price.

DAWN has been the subject of several other reports. Oppenheimer restated a “market perform” rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. Piper Sandler restated an “overweight” rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. JPMorgan Chase & Co. boosted their target price on Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research report on Monday. The Goldman Sachs Group decreased their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Finally, Needham & Company LLC increased their target price on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $39.33.

Day One Biopharmaceuticals Stock Down 13.0 %

Day One Biopharmaceuticals stock opened at $13.21 on Wednesday. The stock has a 50-day simple moving average of $15.23 and a 200 day simple moving average of $13.79. Day One Biopharmaceuticals has a 12-month low of $9.67 and a 12-month high of $17.85. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -5.55 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Monday, February 26th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, sell-side analysts anticipate that Day One Biopharmaceuticals will post -2.66 EPS for the current year.

Insider Buying and Selling

In other news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $16.02, for a total transaction of $160,200.00. Following the completion of the transaction, the insider now directly owns 1,174,662 shares of the company’s stock, valued at approximately $18,818,085.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $16.02, for a total transaction of $160,200.00. Following the completion of the transaction, the insider now directly owns 1,174,662 shares of the company’s stock, valued at approximately $18,818,085.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Samuel C. Blackman sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $16.11, for a total value of $322,200.00. Following the completion of the sale, the insider now directly owns 1,224,662 shares of the company’s stock, valued at approximately $19,729,304.82. The disclosure for this sale can be found here. In the last three months, insiders sold 55,781 shares of company stock valued at $883,160. 8.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently made changes to their positions in DAWN. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Day One Biopharmaceuticals by 130.9% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 2,226 shares of the company’s stock valued at $27,000 after buying an additional 1,262 shares during the last quarter. Quest Partners LLC acquired a new stake in Day One Biopharmaceuticals during the 4th quarter valued at $29,000. Quintet Private Bank Europe S.A. lifted its holdings in Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company’s stock valued at $48,000 after purchasing an additional 1,000 shares during the last quarter. Amalgamated Bank lifted its holdings in Day One Biopharmaceuticals by 35.7% during the 3rd quarter. Amalgamated Bank now owns 8,628 shares of the company’s stock valued at $106,000 after purchasing an additional 2,268 shares during the last quarter. Finally, Exchange Traded Concepts LLC lifted its holdings in Day One Biopharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares during the last quarter. Institutional investors and hedge funds own 87.95% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.